FUNDINGGoogle
Isomorphic Labs raises $2.1B Series B led by Thrive Capital. Founded by Demis Hassabis (Google DeepMind CEO) to commercialize AlphaFold (DeepMind's protein-structure AI) for drug discovery.
Life sciences is the fourth enterprise AI vertical announced in seven days. Labs are dropping a new vertical roughly every four weeks.
Adtech and healthcare are next. Expect drops by EOY 2026. Hassabis leads. AlphaFold's commercial moment after five years of academic adoption. Recursion and Insilico Medicine are now competing on the same fundraising bench.
First AlphaFold-driven AI drug candidate enters clinical pipeline within 18 months. Big Pharma names a primary AI lab partner by Q4.
⚡ Why this matters
- Life sciences declared the next enterprise AI vertical.
- Labs are dropping a new vertical every 4 weeks. Adtech and healthcare are next.
- AlphaFold's commercial moment.
🔍 What happened
- Isomorphic Labs raises $2.1B Series B led by Thrive Capital.
- DeepMind spinout commercializing AlphaFold for drug discovery.
- Demis Hassabis founder.
- One of three best-funded AI drug discovery companies (alongside Recursion, Insilico Medicine).
- Same week as Legal (May 12), SMB (May 13), Financial Services PwC (May 14), Global Health Gates Foundation (May 14).
💬 Smart takes
- Industry framing: life sciences is the fifth vertical AI drop in 7 days.
- Skeptic: Series B at $2.1B for a non-revenue drug discovery play is heroic. AI drug discovery has had multiple high-funding clinical failures.
🧭 Where this goes
- Healthcare and adtech vertical drops by EOY.
- AlphaFold-powered AI drug candidates enter clinical pipeline within 18 months.
- Big Pharma names a primary AI lab partner by Q4.
🎯 Implication
- For PMs at life-sciences vertical-SaaS: write the "partner or compete with DeepMind/Anthropic/OpenAI" memo this quarter.
- For execs: the "AI lab platforms a vertical" pattern is now repeating on 4-week cadence. Plan accordingly.